Selective inhibition of low affinity IgE receptor (CD23) processing

Bioorganic & Medicinal Chemistry Letters
1998.0

Abstract

A series of hydroxamic acids related to the non-selective matrix metalloproteinase inhibitor Batimastat has been prepared, some members of which are potent inhibitors of the processing of the low affinity IgE receptor (CD 23). Increased activity is obtained by appropriate substitution at the alpha-position, whilst selectivity is gained by use of a P1' benzyl group in conjunction with a C-terminal primary amide.

Knowledge Graph

Similar Paper

Selective inhibition of low affinity IgE receptor (CD23) processing
Bioorganic & Medicinal Chemistry Letters 1998.0
Synthesis and structure–activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors
Bioorganic & Medicinal Chemistry Letters 2013.0
N-Hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity
Bioorganic & Medicinal Chemistry Letters 2005.0
Hydroxamate inhibitors of the matrix metallo-proteinases (MMPs) containing novel P1′ heteroatom based modifications
Bioorganic & Medicinal Chemistry Letters 1995.0
Inhibition of Matrix Metalloproteinases by Hydroxamates Containing Heteroatom-Based Modifications of the P1' Group
Journal of Medicinal Chemistry 1995.0
Sodium 1-(12-Hydroxy)octadecanyl Sulfate, an MMP2 Inhibitor, Isolated from a Tunicate of the Family Polyclinidae
Journal of Natural Products 2002.0
Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates
Bioorganic & Medicinal Chemistry 2007.0
Matlystatins, new inhibitors of type IV collagenases from Actinomadura atramentaria. III. Structure elucidation of matlystatins A to F.
The Journal of Antibiotics 1994.0
Design and synthesis of dual inhibitors for matrix metalloproteinase and cathepsin
Bioorganic & Medicinal Chemistry Letters 2002.0
Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidon
Bioorganic & Medicinal Chemistry Letters 1994.0